CA-LEGENDARY-ENTERTAIN
18.7.2022 17:02:12 CEST | Business Wire | Press release
Coming off the heels of the critical and box-office success of the six-time Academy Award® winning first film, Warner Bros. Pictures and Legendary Entertainment have begun production on the highly-anticipated follow-up, “Dune: Part Two,” once again directed by Oscar nominee Denis Villeneuve (“Dune: Part One,” “Arrival,” “Blade Runner 2049”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005284/en/
The big-screen epic continues the adaptation of Frank Herbert’s acclaimed bestseller DUNE with returning stars including: Oscar nominee Timothée Chalamet (“Wonka,” “Call Me by Your Name”), Zendaya (“Spider-Man: No Way Home,” “Malcolm & Marie,” “Euphoria”), Rebecca Ferguson (“Mission: Impossible – Dead Reckoning”), Oscar winner Javier Bardem (“No Country for Old Men,” “Being the Ricardos”), Oscar nominee Josh Brolin (“Glass Onion: A Knives Out Mystery,” “Army of the Dead”), Stellan Skarsgård (the “Mamma Mia!” films, “Avengers: Age of Ultron”), Dave Bautista (the “Guardians of the Galaxy” films, “Thor: Love and Thunder”), Oscar nominee Charlotte Rampling (“45 Years,” “Assassin’s Creed”), and Stephen McKinley Henderson (“Fences,” “Lady Bird”). Also joining the returning cast are Austin Butler (“Elvis,” “Once Upon A Time…In Hollywood”) as the notorious Feyd Rautha and screen legend Christopher Walken (“The Deer Hunter,” “Hairspray”) as the Emperor. Florence Pugh (“Black Widow,” “Little Women”), Léa Seydoux (the “James Bond” franchise and “Crimes of the Future”), and Souheila Yacoub (the “No Man’s Land” series, “Climax”) round out the extensive ensemble cast.
This follow-up film will explore the mythic journey of Paul Atreides as he unites with Chani and the Fremen while on a warpath of revenge against the conspirators who destroyed his family. Facing a choice between the love of his life and the fate of the known universe, he endeavors to prevent a terrible future only he can foresee.
Villeneuve is directing “Dune: Part Two” from a screenplay he co-wrote with Jon Spaihts based on Herbert’s novel. The film is being produced by Denis Villeneuve, Mary Parent, Cale Boyter, Tanya Lapointe and Patrick McCormick. The executive producers are Josh Grode, Herbert W. Gains, Brian Herbert, Byron Merritt, Kim Herbert, Thomas Tull, Jon Spaihts, Richard P. Rubinstein and John Harrison, with Kevin J. Anderson serving as creative consultant.
Once again, Villeneuve is collaborating with Oscar-winning director of photography Greig Fraser (“Lion,” “Zero Dark Thirty,” “Rogue One: A Star Wars Story”), three-time Oscar-nominated costume designer Jacqueline West (“The Revenant,” “The Curious Case of Benjamin Button,” “Quills”), and Oscar-nominated makeup, hair and prosthetic designer Donald Mowat (“Blade Runner 2049”). Multiple Oscar-winning composer Hans Zimmer (“Blade Runner 2049,” “Inception,” “Gladiator,” “The Lion King”) is again on hand to create the score. Villeneuve is also reteaming with Oscar-winning production designer Patrice Vermette (“Arrival,” “Sicario,” “The Young Victoria”), Oscar-winning editor Joe Walker (“Blade Runner 2049,” “Arrival,” “12 Years a Slave”), three-time Oscar-winning visual effects supervisor Paul Lambert (“First Man,” “Blade Runner 2049”), and Oscar-winning special effects supervisor Gerd Nefzer (“Blade Runner 2049”).
“Dune” is being filmed on location in Budapest, Abu Dhabi, Jordan and Italy. The film is slated for a November 17, 2023 worldwide release from Warner Bros. Pictures and Legendary Entertainment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005284/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 08:15:00 CEST | Press release
This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creationIn five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investorsJeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patientsThis fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, toda
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release
Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of
Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 22:05:00 CEST | Press release
Partnership enables early engagement to co-develop cost-effective solutions and accelerate subsea development in Suriname Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea soluti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
